Alpha Tau Medical Ltd Cl A (DRTS)

Dec 18, 2024, 8:30 AM EST - 4 weeks ago

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

Dec 17, 2024, 9:00 AM EST - 4 weeks ago

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

Dec 11, 2024, 8:30 AM EST - 5 weeks ago

Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 6, 2024, 8:30 AM EST - 6 weeks ago

Alpha Tau to Participate in Ladenburg's Oncology Innovators & Investors Symposium

Nov 13, 2024, 8:30 AM EST - 2 months ago

Alpha Tau to Participate in Citi's 2024 Global Healthcare Conference and Piper Sandler's 36th Annual Healthcare Conference

Oct 21, 2024, 8:30 AM EDT - 3 months ago

Alpha Tau Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

Oct 10, 2024, 8:30 AM EDT - 3 months ago

Alpha Tau Treats First Patient with Recurrent Lung Cancer

Sep 20, 2024, 8:30 AM EDT - 4 months ago

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC

Aug 22, 2024, 8:30 AM EDT - 5 months ago

Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Conference

Aug 14, 2024, 4:02 PM EDT - 5 months ago

Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Jun 25, 2024, 8:30 AM EDT - 7 months ago

Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers

May 21, 2024, 8:45 AM EDT - 8 months ago

Alpha Tau to Present at the Jefferies Global Healthcare Conference

May 20, 2024, 4:01 PM EDT - 8 months ago

Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 13, 2024, 8:30 AM EDT - 8 months ago

Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer

May 6, 2024, 8:30 AM EDT - 9 months ago

Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow

May 1, 2024, 8:30 AM EDT - 9 months ago

Alpha Tau to Participate in May Investor Conferences

Mar 25, 2024, 8:50 AM EDT - 10 months ago

Alpha Tau to Present at the Jefferies Radiopharma Innovation Summit

Mar 7, 2024, 4:01 PM EST - 11 months ago

Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update

Feb 26, 2024, 8:30 AM EST - 11 months ago

Alpha Tau to Participate in Barclays 26th Annual Global Healthcare Conference

Dec 20, 2023, 9:15 AM EST - 1 year ago

Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 29, 2023, 8:30 AM EST - 1 year ago

Alpha Tau to Participate in Sidoti Small-Cap Conference

Nov 28, 2023, 8:30 AM EST - 1 year ago

Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer

Nov 20, 2023, 8:30 AM EST - 1 year ago

Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer

Nov 16, 2023, 4:30 PM EST - 1 year ago

Alpha Tau Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 13, 2023, 8:00 AM EST - 1 year ago

Affini-T Therapeutics Appoints Healthcare Capital Markets Veteran Kathy Bergsteinsson, MBA, as Chief Financial Officer

Oct 30, 2023, 8:30 AM EDT - 1 year ago

Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility

Sep 14, 2023, 8:30 AM EDT - 1 year ago

Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel's Hadassah Medical Center

Aug 28, 2023, 4:02 PM EDT - 1 year ago

Alpha Tau Medical Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 24, 2023, 8:00 AM EDT - 1 year ago

Alpha Tau Medical to Participate in September Investor Conferences

Aug 17, 2023, 5:00 PM EDT - 1 year ago

Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT

Aug 2, 2023, 9:00 AM EDT - 1 year ago

Alpha Tau Medical to Present at the Emerging Growth Conference on August 9th, 2023

May 24, 2023, 4:01 PM EDT - 1 year ago

Alpha Tau Medical to Participate in June Investor Conferences

May 23, 2023, 4:01 PM EDT - 1 year ago

Alpha Tau Medical Announces First Quarter 2023 Financial Results and Provides Corporate Update

May 17, 2023, 4:30 PM EDT - 1 year ago

Alpha Tau Expands its Alpha DaRT Treatment to Vulvar Cancer in Novel Clinical Trial with Cambridge University

May 11, 2023, 4:00 PM EDT - 1 year ago

Alpha Tau Announces the Publication of its US Multicenter Pilot Skin Cancer Trial Results in JAMA Network Open

May 3, 2023, 4:00 PM EDT - 1 year ago

Alpha Tau Medical to Present at Guggenheim Radiopharmaceuticals Day

Apr 3, 2023, 9:10 AM EDT - 1 year ago

Alpha Tau and the JGH Announce Alpha DaRT Treatment of First Patient in its Advanced Pancreatic Cancer Clinical Trial

Mar 29, 2023, 4:00 PM EDT - 1 year ago

Alpha Tau Medical to Present at Jefferies Radiopharma Innovation Summit

Mar 12, 2023, 8:30 AM EDT - 2 years ago

Alpha Tau Medical Confirms No Direct Exposure to Silicon Valley Bank

Mar 9, 2023, 4:10 PM EST - 2 years ago

Alpha Tau Medical Announces Full Year 2022 Financial Results and Provides Corporate Update

Mar 8, 2023, 5:00 PM EST - 2 years ago

Alpha Tau Announces Alpha DaRT™ Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial

Mar 1, 2023, 8:30 AM EST - 2 years ago

Alpha Tau Announces Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver Metastases

Feb 21, 2023, 4:00 PM EST - 2 years ago

Alpha Tau to Participate in Citi's 2023 Healthcare Services, Medtech, Tools & HCIT Conference

Dec 13, 2022, 8:00 AM EST - 2 years ago

Alpha Tau to Present at Biotech Showcase and Participate in LifeSci Advisors Corporate Access Event During J.P. Morgan Healthcare Conference in San Francisco in January 2023

Nov 22, 2022, 4:02 PM EST - 2 years ago

Alpha Tau Medical Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 9, 2022, 8:00 AM EST - 2 years ago

Alpha Tau to Present at Upcoming November Investor Conferences

Oct 21, 2022, 4:01 PM EDT - 2 years ago

Alpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society for Radiation Oncology

Sep 19, 2022, 11:30 AM EDT - 2 years ago

OurCrowd Launches $200 Million Global Health Equity Fund in collaboration with the WHO Foundation at the Clinton Global Initiative

BYND

Sep 8, 2022, 4:05 PM EDT - 2 years ago

Alpha Tau Announces the Acceptance in Major Peer-Reviewed Journals (International Journal of Radiation Oncology, Biology, Physics, and Frontiers in Oncology) of Two Landmark Pre-Clinical Studies Demonstrating Significant Potential Synergies Between the Al

Sep 1, 2022, 4:15 PM EDT - 2 years ago

Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer